CALGARY – A three-month-old Winnipeg girl has become the first patient in Canada to receive an experimental and potentially life-saving form of therapy to improve the function of her liver.
Physicians at Alberta Children's Hospital, led by medical geneticist Dr. Aneal Khan, successfully completed a series of liver cell transplants earlier this month on patient Nazdana Jan.
Nazdana was born last August with a Urea Cycle Disorder (UCD), a genetic disease that causes ammonia to build up in the body that, if untreated, would lead to brain damage and death. Ammonia is naturally produced as the body uses protein but, for those with UCDs, the process of converting ammonia to urea (a harmless substance which gives urine its yellow colour) does not work properly.
The condition is incurable and very rare: Alberta Children's Hospital treats about two children with a UCD per year. In Canada, about 50 babies are born annually with the condition.
Each time ammonia builds up, there is a risk of neurological damage but transplanted liver cells are expected to help Nazdana's liver to keep the ammonia down to safe levels.
"We have been monitoring Nazdana closely and are happy to report that she has tolerated the liver cell transplant well, she is stable and can return home to Winnipeg," says Dr. Khan, who is also an assistant professor of medical genetics and pediatrics at the University of Calgary, and a member of the U of C-AHS Alberta Children's Hospital Research Institute for Child and Maternal Health. "This could represent a big leap forward in managing these cases. It's a promising new bridge therapy that could improve the odds of Nazdana surviving until she is able to undergo a liver transplant."
The long-term stabilization of ammonia levels resulting from liver cell infusion buys children time until a matching liver can be found and transplanted.
To date the procedure has been performed in Germany, including an operation on a Canadian baby, and in a handful of centres in the U.S.
Without conventional treatment, most newborns with a UCD die within the first two weeks of life. Special medications and a protein-restricted diet improve survival rates but the brain remains exposed to high ammonia levels and even children who survive have a high risk of brain damage. The only long-term treatment is a liver transplant but a transplant in a small child has less chance of success and there is limited availability of organs.
Nazdana's procedures took place over six days earlier this month at Alberta Children's Hospital, with each infusion taking about an hour. It is part of a research trial sponsored by the biotechnology firm Cytonet LLC, which covered all costs for the procedures, hospitalizations, blood tests and related expenses. Through a complex process, Cytonet transforms liver cells from donor organs that would otherwise go to waste, into cells that can be transplanted.
Nazdana currently weighs about 4.5 kilograms and ideally will have to reach a weight of at least seven kilograms before the chances of a successful organ transplant improve. In the meantime, the small amount of transplanted liver cells allow her to get the nutrition, including protein, she needs to grow while helping to keep her ammonia under control.
Nazdana's father, Jouhar Ali, is grateful for the care his daughter has received.
"The health care people – the nurses and the doctors – they have all been outstanding. I have no words to explain it," says Ali. "I really appreciate and am very thankful for what they have done."
The current study allows for three patients to be enrolled. Dr. Khan expects the next candidate for liver cell transfusion will be a baby from southern Alberta who is currently hospitalized for management of high ammonia levels.
"It's largely because of the organizational support we have through Alberta Health Services and the University of Calgary that we were able to be the first in Canada to perform this therapy,"
Dr. Khan says. "In particular, it took the coordination and support of a great many people at Alberta Children's Hospital to make this happen."
Alberta Health Services is the provincial health authority responsible for planning and delivering health supports and services for more than 3.8 million adults and children living in Alberta. Its mission is to provide a patient-focused, quality health system that is accessible and sustainable for all Albertans.
Still photos and video of one of Nazdana's liver cell infusion procedures are available at ftp://208.118.126.84 NOTE: videos are too large to stream; they must be downloaded for playback.
User name: media
Password: share
Folder: ACH-CELL-THERAPY
For media inquiries, contact:
Greg Harris
AHS Communications
403-943-2911
403-619-3108 (cell)
About The Alberta Children's Hospital Research Institute for Child and Maternal Health (ACHRI)
ACHRI is a multi-disciplinary Partnership Institute of the University of Calgary, Alberta Health Services and the Alberta Children's Hospital Foundation – the membership of which encompasses the Faculties of Arts, Engineering, Medicine, Veterinary Medicine, Nursing, Kinesiology, Science and Social Work. http://research4kids.ucalgary.ca/
About the University of Calgary's Faculty of Medicine
UCalgary's Faculty of Medicine is a national leader in health research with an international reputation for excellence and innovation in health care research, education and delivery. The Faculty of Medicine trains the next generation of health practitioners and moves new treatments and diagnostic techniques from the laboratory bench to the hospital bedside, improving patient care. For more information, visit medicine.ucalgary.ca or follow them on twitter.com.
About Cytonet
Cytonet is an internationally active biotechnology company which is located in Weinheim and Heidelberg in Germany and in Durham, NC in the U.S. The company develops and produces cell therapeutic products. Cytonet's goal is to provide alternatives to existing therapies for many diseases with a particular emphasis on liver diseases. Cytonet is a pioneer and leader in the field of regenerative medicine. For the past several years, Cytonet has worked with internationally-leading metabolism and neonatal centers to study its liver cell therapy, which uses healthy and metabolically functional human liver cells collected from donated livers not suitable for transplant for infusion to treat urea cycle disorders in children. For more information, please visit Cytonet's website at http://www.cytonetllc.com/